-

Nomi Health Supports Utah Department of Health with Vaccine Program for 5-11 Year Olds

No-cost Pfizer vaccine available with no appointment required

OREM, Utah--(BUSINESS WIRE)--Nomi Health, the direct healthcare company rewiring how healthcare is paid for and delivered, is pleased to extend its support to Utah’s Department of Health by supporting the vaccination of pediatrics, ages 5-11 years old.

Starting today, eligible residents between the ages of 5 and 11 years old can be brought to one of 4 community clinics operated by Nomi Health for their first dose of the Pfizer vaccine.

All 4 locations are open Monday - Saturday from 9am - 6pm:

West Valley – Salt Lake County
Centennial Park
5415 W 3100 S., West Valley City

Lindon – Utah County
Walmart
585 N. State Street, Lindon

Layton – Davis County
Ellison Park
700 N. 2200 W., Layton

Ogden – Weber County
Ogden Regional
5475 S. 500 E., Ogden

“The CDC has released their recommendation that children between the ages of 5 and 11 years can begin receiving the Pfizer-BioNTech pediatric vaccine,” said Dr. June Steely, Nomi Health Medical Director. “Nomi Health staff have been trained to accommodate pediatric patients, as we extend our track record of keeping Utahans safe and keeping schools, workplaces and communities open.”

All locations are taking walk ups on a first come, first served basis. Currently wait times average 1-3 minutes. Pre-registration is not necessary but is suggested to ensure a quick experience. Registration is available in both English and Spanish at https://getmyshot.utah.gov/. For any questions, the vaccine program helpline is 801-783-1665, where support is accessible in both English and Spanish.

For a complete list of Nomi Health vaccination locations, please visit: https://getmyshot.utah.gov/.

About Nomi Health

Nomi Health is a direct healthcare company focused on making healthcare actually work for those who buy it for their states, organizations and constituents. We’re a team of over 2,000--each actively working to connect buyers and healthcare providers directly to lower costs, deliver care solutions to all and rewire the health system to run in real time. From the front lines of COVID testing and vaccination serving over 10 million Americans and more than 40,000 patients each day, to building new ecosystems of buyers such as States and Counties without middlemen, Nomi delivers a solution for our nation’s leaders seeking to widen access to care while lowering cost of care. Visit us @NomiHealth and www.nomihealth.com.

Contacts

Jenny Olson
mPR, Inc. for Nomi Health
jenny@mpublicrelations.com
310-773-2568

Nomi Health


Release Versions

Contacts

Jenny Olson
mPR, Inc. for Nomi Health
jenny@mpublicrelations.com
310-773-2568

More News From Nomi Health

CerpassRx Launches AI Engine Powered By Waltz Health to Deliver Real-Time Savings and Spend Management for Specialty Drugs

DALLAS & CHICAGO--(BUSINESS WIRE)--CerpassRx, a leader in pharmacy benefit management (PBM), today announced the launch of the Intelligent Specialty Engine, an AI-enabled platform powered by Waltz Health to manage specialty drug spend. CerpassRx’s innovative approach includes real-time analytics and specialty spend management capabilities that drive significant cost savings, improve transparency and optimize the specialty drug experience for health plan customers and their members – or self-ins...

CareSource and Nomi Health Launch Innovative Partnership to Improve Healthcare Access and Outcomes

DAYTON, Ohio--(BUSINESS WIRE)--CareSource, a non-profit health plan with over 2 million members, has selected Nomi Health to partner with it in launching a new comprehensive effort to help close gaps in healthcare access and outcomes for its Medicaid members across Ohio, Georgia, and Indiana. This collaboration aims to enhance access to essential healthcare services and improve overall health outcomes for people facing barriers to care. "This partnership with Nomi Health represents a significan...

Weight Loss Drugs Weigh Heavy on Employer Health Plans

OREM, Utah--(BUSINESS WIRE)--A meteoric rise in the popularity of glucagon-like peptide-1 (GLP-1) medications such as Ozempic, Wegovy and Mounjaro is creating financial challenges for employer-sponsored health plans. New data from Nomi Health, a company changing healthcare economics, reveals that spending on these diabetes and weight loss drugs went up 253% from 2020 to 2023, surpassing $1 billion last year and making up nearly 10% of total prescription costs for employers. Nomi Health analyzed...
Back to Newsroom